2017 CPhI North America – Exhibitor Showcase Sponsors

CPhI North America assembled leading pharmaceutical professionals to provide a forum for solving some of the pharmaceutical industry’s most pressing challenges.

One of the highlights of the CPhI North America conference was LGM Pharma’s presentation at the Exhibitor Showcase. The presenter was LGM Pharma’s Commercial Director, Gideon Schurder. He gave an in-depth look at the calamitous effects of recent FDA warning letters and import bans and how this affects the pharmaceutical industry, API manufacturers and formulation companies.

Attendee roles covered the complete supply chain. Pharmaceutical executives along with R&D, compliance, regulatory, manufacturing, supply chain, packaging, and procurement professionals gathered to build connections, to capitalize on emerging trends, further innovation, and tackle industry challenges.

Some of the top countries in attendance were the U.S., China, India, Canada, UK, South Korea, Japan, Germany, France and Spain.

The Exhibitor Showcase titled, “The Unfortunate Aftermath of the US-FDA Slamming API Factories.” brought forth prime examples of how API factories should have acted to avoid getting themselves into trouble. Mr. Schurder also illustrated how all of this affects patients and what the Trump administration could do in order to mitigate the outcome.

“We were pleased with the accomplishments of LGM Pharma at the CPhI North America conference,” stated Steve Beagle, LGM’s Senior Vice President of Business Development. “We brought our client centric business development model to our clients’ projects showcasing our exceptional sourcing capabilities and manufacturer relationships.”


View the “The Unfortunate Aftermath of the US-FDA Slamming API Factories” video/slide presentation below:

Steve Beagle Appointed New Senior Vice President of Business Development

Steve BeagleNASHVILLE, Tennessee — LGM Pharma recently announced that Mr. Steve Beagle would be joining the organization as the Senior Vice President of Business Development.

In that capacity, Mr. Beagle will be heading up all marketing and sales activities for the company and will be working out of LGM’s new business development offices, based in New York City.

Immediately prior to joining LGM, Mr. Beagle served as North America Director of MSN Pharmaceuticals, Inc. Prior to MSN, he was North America Territory Director for Dr. Reddy’s CPS custom chemistry business. Mr. Beagle has extensive professional experience in the pharmaceutical industry and has also held key roles at DSM, BASF, Rohner AG, American Cyanamid and Hovione. He holds a BSc. from the University of Connecticut and studied at the Arnold and Marie Schwartz NY College of Pharmacy.

Speaking about his future vision for LGM, Mr. Beagle stated, “Even as a relatively young company, the key management team of LGM Pharma has already built a sophisticated global sourcing, supply chain, and sales and marketing platform with epicenters in Israel, India, China and the US. The hyper-competitive and ever-involving API landscape demands cost effective solutions. With their unique expertise in complex supply chain, API sourcing, and management, LGM Pharma is well positioned to service clients looking to outsource R&D and commercial activities. I am pleased to be joining the LGM team with the goal of building upon LGM’s existing strategic relationships while also targeting new opportunities throughout North America.”

LGM Pharma Representatives Attend CPhI Conference in Spain

CPhI Conference NASHVILLE, Tennessee — Representatives from LGM Pharma, a leading supplier of active pharmaceutical ingredients to various global pharmaceutical firms, headquartered in Nashville, Tennessee with administrative offices in Boca Raton, Florida, recently attended the CPhI Worldwide conference in Madrid, Spain. CPhI is the world’s leading pharmaceutical platform that brings together pharma ingredients manufacturers, suppliers and buyers. The conference agenda tackled the most timely and business critical issues facing the pharmaceutical industry today.

During the conference, representatives of LGM Pharma met with strategic manufacturers to discuss involvement in the development of commercial products. Industry updates and information were exchanged and insight into various regulatory industry intelligence was shared.

According to Mendy Schurder, LGM Director and COO, “By attending the CPhI conference, we had the opportunity to gather the latest market trends, explore key case study insights and benefit from exceptional networking opportunities all within three days. Although we had a full meeting schedule, LGM considers this the most vital venue to meet with clients, manufacturers and potential new business partners.”

“Given the limited time with each business partner, LGM was still able to have meetings with, and come away with, key commitments to some late phase development projects with a specialty pharma client in the new drug delivery space,” said Robert Hoppes, LGM Director of Sales. “Our industry experience enables us to support our clients throughout the entire pathway of drug development, from drug discovery through commercial production.”

“In today’s world, international business is easily accomplished, where everything is readily accessible and instantaneous,” stated Albert Miseje, LGM Vice president, New Business Development. “However, it’s still essential to go back to the basics and conduct face to face meetings. This value still holds true today.”

The CPhI Worldwide conference hosted over 36,000 visiting pharma professionals, 2,500 exhibitors from more than 150 countries and more than 100 industry seminars, covering every sector in four massive halls.

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to Contract manufacturers and various global pharmaceutical firms involved in the manufacturing, research and development of a wide range of therapeutic chemical entities. In its commitment to improving health opportunities all over the world, LGM Pharma has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients.

Drug Shortages Loom as Obamacare Commences

FDA Drug ShortagesDrug shortages continue to worry healthcare industry workers, especially with the launch of Obamacare on October 1, 2013. While notification has been prompt from the FDA as to which drugs are in danger of becoming in short supply, many medications which are already minimally available have not seen a respite.

Falling Short

The once planned generic program created by the FDA has fallen short, as there is a significant lack of manufacturers in the drug marketplace. As of mid-September 2013 active drug shortages were recorded at high levels. In fact, the close of the third quarter of 2013 showed 302 ongoing active drug shortages, which was greater than the amount at the close of the third quarter in 2012, which logged 282 shortages. The situation is not projected to get better anytime soon, and experiencing a drug shortage is becoming more commonplace.

The Impact

ASCO annua meeting 2013Cancer patients have experienced a particularly difficult time during this current pharmaceutical snafu. At the beginning of the summer of 2013 a startling report regarding cancer drug shortages was revealed at the American Society of Clinical Oncology (ASCO) annual meeting. Of the cancer specialists nationwide reporting, 83 percent of these specialists reported a drug shortage in the most recent six month period of time, which negatively affected their practice. A staggering 92 percent of these physicians stated that the current drug shortage has also adversely affected their patients’ health and quality of treatment. It is obvious that the United States, as well as many countries worldwide have a dangerous situation brewing, which needs to be remedied as soon as possible.

Supplying API’s During the Drug Shortage

Clients can find current drug shortage API’s available on LGM Pharma’s website, such as:

Product Name CAS# TAPI API Availability
Acyclovir Acyclovir 59277-89-3
Alteplase Alteplase 105857-23-6
Doxorubicin Hydrochloride Doxorubicin Hydrochloride 25316-40-9
Fentanyl Fentanyl 437-38-7
Furosemide Furosemide 54-31-9
Ondansetron Hydrochloride Ondansetron Hydrochloride 110707-92-1
Tobramycin Tobramycin 32986-56-4

Research and development teams need to easily access quality API’s. LGM Pharma is the optimum source for these quality pharmaceutical products, as well as a continued support system for all clients throughout the research and development process. Clients seeking any of the API products currently experiencing a drug shortage should contact LGM Pharma immediately. LGM Pharma is a preferred supplier of over 2,500 API’s to clients worldwide.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM Pharma COO Attends Event at the Florida Governor’s mansion

Mendy Schurder - COO LGM Pharma, Florida Governor Rick Scott, and First Lady Ann

Mendy Schurder – COO LGM Pharma, Florida Governor Rick Scott, and First Lady Ann

Newly elected Florida Governor Rick Scott and First Lady Ann hosted the annual Menorah Lighting at the Governor’s mansion on December 21, 2011.

Many guests came from throughout the state for the celebration, including our very own LGM Pharma COO, Mendy Schurder.

The event was covered by the local media and appeared in the news on TV and was on the front page of the newspaper the next day.

At the event, Shliach Rabbi Schneur Oirechman mentioned that Governor Scott is the 3rd Florida Governor to host this Menorah lighting, following annual Menorah lightings with Governors Jeb Bush and Charlie Crist. Oirechman thanked the Governor and First Lady for continuing the tradition.

Rabbi Oirechman wished the Governor continued success in his mission of spreading the light in the ‘Sunshine state’.

Governor Scott spoke about his recent trade mission trip to Israel and thanked Rabbi Oirechman and his wife Chanie for joining him there. He said that he has gained a lot from his inspiring visit to the Western Wall on Friday night and from visiting Yad Vashem.

Rabbi Oirechman presented to the Governor a picture of his recent visit to the Wall and then Ari Oirechman lit the menorah, followed by the singing of Chanukah songs.

Rabbi Shalom Loeub, the newest shliach to the area and coordinator of the event, spoke as well.

We thank the governor for this wonderful opportunity to take part in such a joyous and meaningful holiday!